DDInter1042 DDInter1346
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]
Orciprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Orciprenaline {u} (Compound) resembles {v} (Compound) Fenoterol
Orciprenaline {u} (Compound) resembles {v} (Compound) Terbutaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
Orciprenaline {u} (Compound) upregulates {v} (Gene) DDX10
Orciprenaline {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Orciprenaline {u} (Compound) downregulates {v} (Gene) SLC2A6
Orciprenaline {u} (Compound) causes {v} (Side Effect) Dizziness
Orciprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Betamethasone
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Orciprenaline (Compound) resembles Fenoterol (Compound)
Orciprenaline (Compound) resembles Terbutaline (Compound)
Orciprenaline (Compound) treats asthma (Disease)
Orciprenaline (Compound) binds ADRB2 (Gene)
Orciprenaline (Compound) upregulates DDX10 (Gene)
Orciprenaline (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Orciprenaline (Compound) downregulates SLC2A6 (Gene)
Orciprenaline (Compound) causes Dizziness (Side Effect)
Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Betamethasone